Zhang Fan, Chu Jinjin, Wang Fan
Department of Radiotherapy, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, P.R. China.
Oncol Lett. 2017 Aug;14(2):1303-1308. doi: 10.3892/ol.2017.6281. Epub 2017 May 31.
The present study aimed to determine cyclooxygenase 2 (COX-2) and survivin expression levels in glioma tissues, and to investigate their association with clinicopathological factors and patient survival. Immunohistochemistry was performed to evaluate COX-2 and survivin expression levels in paraffin-embedded surgically resected tissues from 70 patients with glioma and 7 individuals with normal brain tissues. The association between COX-2 and survivin expression levels and clinicopathological features was investigated using the χ test, and the survival time was analyzed using the Kaplan Meier method with log-rank test. COX-2 and survivin were overexpressed in glioma tissues, and higher expression levels were observed in glioma tissues of histological grades III-IV compared with those in grade I-II tumor tissues (P<0.05); however, the expression levels were not associated with gender, age, tumor size or location (P>0.05). There was a significant positive association between the expression levels of COX-2 and survivin in the glioma tissues. Additionally, COX-2 and survivin expression levels were significantly negatively correlated with the rate of survival. In conclusion, COX-2 and survivin expression is positively associated with the pathological grade of a glioma and may contribute to glioma tumorigenesis. Therefore, COX-2 and survivin may be sensitive predictors of a negative clinical prognosis for patients with glioma.
本研究旨在测定胶质瘤组织中环氧合酶2(COX-2)和生存素的表达水平,并探讨它们与临床病理因素及患者生存情况的关系。采用免疫组织化学方法评估70例胶质瘤患者手术切除的石蜡包埋组织及7例正常脑组织中COX-2和生存素的表达水平。采用χ检验研究COX-2和生存素表达水平与临床病理特征之间的关系,采用Kaplan-Meier法和对数秩检验分析生存时间。COX-2和生存素在胶质瘤组织中过表达,与I-II级肿瘤组织相比,III-IV级胶质瘤组织中观察到更高的表达水平(P<0.05);然而,表达水平与性别、年龄、肿瘤大小或位置无关(P>0.05)。胶质瘤组织中COX-2和生存素的表达水平之间存在显著正相关。此外,COX-2和生存素表达水平与生存率显著负相关。总之,COX-2和生存素表达与胶质瘤的病理分级呈正相关,可能有助于胶质瘤的发生。因此,COX-2和生存素可能是胶质瘤患者不良临床预后的敏感预测指标。